A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant

2017-03

Davis, Ian D

Quirk, Juliet

Morris, Leone

Seddon, Lauren

Tai, Tsin Yee

Whitty, Genevieve

Cavicchiolo, Tina

Ebert, Lisa

Jackson, Heather

Browning, Judy

MacGregor, Duncan

Wittke, Frederick

Winkels, Gregor

Alex, Regina

Miloradovic, Lena

Maraskovsky, Eugene

Chen, Weisan

Cebon, Jonathan S

ISCOMATRIX™ adjuvant

NY-ESO-1

Antigens

Clinical trial

Dendritic cells

Journal Article

10.2217/imt-2016-0132

Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. CONCLUSION: This method was feasible and safe but was minimally immunogenic.

link

Immunotherapy 2017; 9(3): 249-259

Immunotherapy